

## CLINICAL BIOCHEMISTRY REVIEWS

### CONTENTS

Manuel Buchwald	1	<b>Use of Cultured Human Cells for Biochemical Analysis</b>
	2	I. Introduction
	2	II. Cultured Human Cells
	6	III. General Aspects of Cell Culture
	11	IV. Sources of Variability
	14	V. Conclusions
J.C. Crawhall	21	<b>A Review of the Clinical Presentations and Laboratory Findings in Two Uncommon Hereditary Disorders of Sulfur Amino Acid Metabolism: Beta-Mercaptolactate-Cysteine Disulfiduria and Sulfite Oxidase Deficiency</b>
	22	I. Introduction
	22	II. Clinical Presentations of Beta-Mercaptolactate-Cysteine Disulfiduria
	24	III. Laboratory Criteria for Establishment of the Diagnosis of Mercaptolactate-Cysteine Disulfiduria
	25	IV. Clinical Presentation of Sulfite Oxidase Deficiency
	26	V. Laboratory Criteria for the Establishment of the Diagnosis
	26	VI. Antenatal Detection of Combined Xanthine and Sulfite Oxidase Deficiencies
	28	VII. Conclusion
Jean-Claude Dreyfus and Axel Kahn	33	<b>Red Cell Enzymopathies (Molecular Mechanisms)</b>
	34	I. Introduction
	36	II. Enzymopathies of the Glycolytic Pathway
	40	III. Enzymopathies of Redox Pathways
	45	IV. Purine and Pyrimidine Metabolism
	46	V. Conclusion
Henry C. Ford	55	<b>Is There a Consistent, Specific Serum or Plasma Abnormality in Patients with Multiple Sclerosis?</b>
	56	I. Introduction
	56	II. Non-Protein Components
	59	III. Proteins
	73	IV. Demyelinating Factors and Neuroelectric Blocking Factors
	74	V. Conclusions
Jiri Frohlich and Roger McLeod	87	<b>Lecithin: Cholesterol Acyltransferase (LCAT)</b>
	88	I. Introduction
	88	II. LCAT and Lipoprotein Metabolism
	91	III. Enzymatic Properties of LCAT
	92	IV. Assessment of LCAT Activity
	93	V. Purification and Characterization of LCAT
	94	VI. LCAT and Erythrocyte Lipids
	95	VII. LCAT Deficiency States
	104	VIII. Assay of LCAT Activity as a Diagnostic Test
	104	IX. Conclusion

J. Thomas Hindmarsh	117	<b>Clinical Disorders of Porphyrin Metabolism</b>
	117	I. Introduction
	118	II. Heme Synthesis
	120	III. Control of Synthesis
	122	IV. Porphyrin Excretion, Normal and Abnormal
	124	V. The Porphyrins
	124	VI. Congenital Erythropoietic Porphyrin
	126	VII. Porphyrin Cutanea Tarda (PCT)
	129	VIII. Toxic Porphyrin
	129	IX. Hepatoerythropoietic Porphyrin
	130	X. Hereditary Coproporphyrin
	130	XI. Protoporphyrin
	130	XII. Acute Intermittent Porphyrin
	132	XIII. ALA Dehydratase Deficiency
	132	XIV. Porphyrin Variegata
	134	XV. Hereditary Coproporphyrin
	134	XVI. Investigation of a Suspected Case of Porphyrin
	134	XVII. Methods
David S.C. Lee	141	<b>Human Serum Vitamin B<sub>12</sub> Assay Methods—A Review</b>
	142	I. Introduction
	142	II. Absorption and Transport of Vitamin B <sub>12</sub>
	142	III. Clinical and Analytical Perspectives
	144	IV. Reported Methods for Serum B <sub>12</sub> Assays
	150	V. Assessment of Serum B <sub>12</sub> Assay Methods
	151	VI. Conclusion
Vincent Marks, Wynne Aherne, Judie English and Josephine Arendt	159	<b>Chronopharmacology</b>
	159	I. Introduction
	160	II. Pharmacokinetics, Pharmacodynamics and Toxicity
	163	III. Antineoplastic Drugs
	168	IV. Conclusion
Vincent Marks	173	<b>How Our Food Affects Our Hormones</b>
	173	I. Introduction
	174	II. Neural Control of Hormone Secretion
	175	III. Indirect Effects
	176	IV. Gut Hormones
	177	V. Entero-Insular Axis
	177	VI. GIP
	179	VII. Obesity and Diabetes
	182	VIII. Food Texture
	182	IX. Conclusions
Morris R. Pudek	187	<b>Antibody Interference with Biochemical Tests and Its Clinical Significance</b>
	188	I. Introduction
	190	II. Enzymes
	198	III. Hormones
	204	IV. Plasma Proteins
	207	V. Miscellaneous
Morton K. Schwartz	217	<b>Immunoassay of Enzymes—An Overview</b>
	217	I. Introduction
	218	II. Acid Phosphatase
	219	III. Alkaline Phosphatase
	221	IV. Amylase
	221	V. Aspartate Aminotransferase
	223	VI. Creatine Kinase

	225	VII. Lactate Dehydrogenase
	226	VIII. Lysozyme (Muramidase)
	227	IX. Neuron Specific Enolase
	228	X. Nucleases
	229	XI. Phosphohexose Isomerase
	230	XII. Terminal Deoxynucleotidyl Transferase
	230	XIII. Enzymes in Chemotherapy
	231	XIV. Conclusion
R.W.E. Watts	239	<b>Purine Enzymes and Immune Function</b>
	239	I. Introduction
	241	II. Purine Nucleotide Synthesis <i>De Novo</i>
	243	III. The Interconversion, Conservation and Degradation of Purine Nucleotides, Nucleosides and Bases
	245	IV. Adenosine Deaminase (ADA)
	246	V. Purine Nucleoside Phosphorylase (PNP)
	247	VI. Ribonucleoside Diphosphate Reductase (Ribonucleotide Reductase)
	249	VII. Adenosylhomocysteinase [S-Adenosylhomocysteine Hydrolase] and the S-Adenosylhomocysteine Pathway
	253	VIII. 5'Nucleotidase and Immunodeficiency
	253	IX. The Cellular Uptake of Purines, Purine Nucleosides and Nucleotides
	254	X. Lymphocyte Transformation: Changes in Pyridine Nucleotide Pools
	255	XI. Lymphocyte Transformation: Cell Surface-Purine Synthesis Interrelationships
Tai-Wing Wu	267	<b>Delta Bilirubin—The State of the Art and Future Prospects</b>
	268	I. Introduction
	268	II. The Central Dogmas
	270	III. Quantification of Serum Bilirubins
	278	IV. Future Prospects

